Midatech has announced that the first patient in the Phase IIa study for its transbuccal insulin (MSL-001) has been treated. MSL-001 is the lead programme from the gold nanoparticle (GNP) platform and represents the largest element within our rNPV model, valued at £67.3m (242p a share). Our rNPV model, excluding the proposed DARA BioSciences acquisition, suggests a current value of £134.7m (485p a share).
23 Jul 2015
Buccal strip insulin starts Phase IIa diabetes trial
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Buccal strip insulin starts Phase IIa diabetes trial
- Published:
23 Jul 2015 - Author:
- Pages:
Midatech has announced that the first patient in the Phase IIa study for its transbuccal insulin (MSL-001) has been treated. MSL-001 is the lead programme from the gold nanoparticle (GNP) platform and represents the largest element within our rNPV model, valued at £67.3m (242p a share). Our rNPV model, excluding the proposed DARA BioSciences acquisition, suggests a current value of £134.7m (485p a share).